Abstracts tagged "BAFF"

Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Simon Bowman¹, Robert Fox ², Thomas Dörner ³, Xavier Mariette ⁴, Athena Papas ⁵, Thomas Grader-Beck ⁶, Benjamin A. Fisher ⁷, Filipe Barcelos ⁸, Salvatore De Vita ⁹, Hendrik Schulze-Koops ¹⁰, Robert J. Moots ¹¹, Guido Junge ¹², Janice Woznicki ¹³, Monika Sopala ¹², Wen-Lin Luo ¹³ and Wolfgang Hueber ¹², ¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ²Scripps Memorial Hospital and Research Institute, La Jolla, California, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Tufts School of Dental Medicine, Massachusetts, ⁶Johns Hopkins University, Baltimore, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, ⁸Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, ⁹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ¹⁰Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ¹¹Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ¹²Novartis Pharma AG, basel, Switzerland, ¹³Novartis Pharmaceuticals Corporation, New Jersey
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
Abstract Number: 2287 • 2019 ACR/ARP Annual Meeting
Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
Hindi Stohl ¹, Ning Yu ² and William Stohl², ¹Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Immunologic, angiogenic, and anti-angiogenic factors have been associated with spontaneous abortion (SAB), yet early identification of those pregnant women who ultimately undergo SAB remains…
Abstract Number: 17 • 2018 ACR/ARHP Annual Meeting
Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab
Amer khojah^1,2, Victoria Hans³, Wilfredo Marin⁴, Gabrielle A. Morgan⁴ and Lauren M. Pachman^5,6,7, ¹Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Pediatric Allergy Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Rituximab is used for the treatment of juvenile dermatomyositis (JDM) with variable success. Some of this variability is presumed to be related to the…
Abstract Number: 111 • 2018 ACR/ARHP Annual Meeting
BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Takashi Matsushita¹, Tadahiro Kobayashi², Yasuhito Hamaguchi², Minoru Hasegawa³, Manabu Fujimoto⁴ and Kazuhiko Takehara¹, ¹Kanazawa University, Department of Dermatology, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan, ³University of Fukui, Department of Dermatology, Fukui, Japan, ⁴University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Over 90% of patients with SSc are positive for autoantibodies. In…
Abstract Number: 1092 • 2018 ACR/ARHP Annual Meeting
Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE
Andrew Vasconcellos¹, John Marken¹, Sladjana Skopelja-Gardner¹, Christian Lood² and Natalia V. Giltiay¹, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: The production of anti-nuclear auto-antibodies (Ab) and the formation of immune complexes (IC) are hallmarks of Systemic Lupus Erythematosus (SLE). Enhanced neutrophil (PMN) activation…
Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
Abstract Number: 1837 • 2017 ACR/ARHP Annual Meeting
Development of Murine SLE in the Absence of BAFF
William Stohl¹, Ning Yu¹, Samantha Chalmers², Chaim Putterman³ and Chaim O. Jacob¹, ¹Division of Rheumatology, Keck School of Medicine of University of Southern California, Los Angeles, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: BAFF is a vital survival and differentiation factor for B cells. In human SLE, clinical efficacy with any of 4 different BAFF antagonists is…
Abstract Number: 20 • 2017 ACR/ARHP Annual Meeting
Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
Keiko Yoshimoto¹, Noriyasu Seki², Katsuya Suzuki³, Kunio Sugahara⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²3) Research Unit/Immunology & Inflammation, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan, ⁴Research Unit/Immunology & Inflammation, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan
Background/Purpose: We have reported that soluble BAFF (sBAFF) robustly increased IL-6 production by peripheral monocytes of patients with primary Sjögren’s syndrome (pSS) and that the…
Abstract Number: 576 • 2017 ACR/ARHP Annual Meeting
Immunosignature-Based Diagnosis and Prediction of Therapeutic Response Enables Retrospective Patient Stratification in a Phase IIa Clinical Trial for VAY736 in Primary Sjögren’s Syndrome
Robert Gerwien¹, Theodore M. Tarasow², Jonathan Melnick², Anna Lei³, Arvind Kinhikar⁴, Julie Doucet⁵, Remi Kazma⁵, Paul Maguire⁴, Irina Koroleva⁶, Giulio Macchiarella⁴, Alexandre Avrameas⁵, Marie-Anne Valentin⁵, Stephen Oliver⁵ and Alessandra Vitaliti⁵, ¹HealthTell, Inc, san ramon, CA, ²HealthTell, Inc., San Ramon, CA, ³Health Tell, San Ramon, CA, ⁴Novartis, Cambridge, MA, ⁵Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁶Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA
Background/Purpose: Although patient stratification can improve the success rate of clinical trials, efforts to apply this strategy to autoimmune studies such as Sjögren’s syndrome are…
Abstract Number: 875 • 2017 ACR/ARHP Annual Meeting
Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736
Petra Budde¹, Julie Doucet², Hans-Dieter Zucht¹, Remi Kazma², Paul Maguire², Alexandre Avrameas², Marie-Anne Valentin², Stephen Oliver², Peter Schulz-Knappe¹ and Alessandra Vitaliti², ¹Protagen AG, Dortmund, Germany, ²Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland
Background/Purpose: Overexpression of B cell activating factor (BAFF) in salivary glands contributes to the pathogenesis of primary Sjögren’s syndrome (pSS) by promoting autoantibody (AAB) production.…
Abstract Number: 888 • 2017 ACR/ARHP Annual Meeting
Phase 3 Trial Results with Blisibimod, a Selective Inhibitor of B-Cell Activating Factor, in Subjects with Moderate-to-Severe Systemic Lupus Erythematosus
Joan T. Merrill¹, Renee S. Martin², William Shanahan², Morton Scheinberg³, Kenneth C. Kalunian⁴ and David Wofsy⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Anthera, Hayward, CA, ³Department of Immunology, Center for Clinical Immunology, Sao Paulo SP, Brazil, ⁴Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁵Rheumatology, UCSF, San Francisco, CA
Background/Purpose: The Phase 3 CHABLIS-SC1 trial (NCT01395745) evaluated blisibimod, an inhibitor of B-cell activating factor (BAFF), in SLE. Prior SLE trials suggested that treatments are…
Abstract Number: 1463 • 2017 ACR/ARHP Annual Meeting
Interaction between Methotrexate and BAFF for Preventing Immunization Against TNF-α Inhibitors By Increasing Adenosine and Regulatory B-Cell Subsets
Samuel Bitoun¹, Gaetane Nocturne², Bineta Ly³, Juliette Pascaud⁴, Alain Pruvost⁵ and X Mariette⁶, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ⁵CEA - DRF/iBiTec-S - LabEx LERMIT - MetaboHUB-Paris, Gif sur Yvette, France, ⁶INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: TNFα inhibitors (TNFi) can be immunogenic in patients with autoimmune diseases. B-cell activating factor transgenic mice (BAFFtg) are a model of autoimmune disease since…
Abstract Number: 1667 • 2017 ACR/ARHP Annual Meeting
Increased Levels of BAFF in SLE Patients Correlates with Neutrophil Activation and Autoantibody Production
Andrew Vasconcellos¹, John Marken¹, Ting Wang^1,2, Christian Lood³ and Natalia V. Giltiay¹, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Neutrophil (PMN) activation and neutrophil extracellular trap (NET) formation are implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE), particularly in the acceleration of…
Abstract Number: 1823 • 2017 ACR/ARHP Annual Meeting
Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Samuel Bitoun¹, Pierre Dönnes², Aline Doublet³, Kimberly Florence⁴, Agnes Hincelin-Mery⁵, Gaetane Nocturne⁶, Mattieu Allez⁷, N Ruperto⁸, Marc Pallardy⁹ and Xavier Mariette¹⁰, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²SciCross AB, Skövde, Sweden, ³Department of Rheumatology, Kremlin-Bicêtre hospital INSERM U1184, Le Kremlin Bicêtre, France, ⁴Immunogenicity and Clinical Immunology, GlaxoSmithKline, King of Prussia, PA, ⁵Sanofi, Chilly-Mazarin, France, ⁶INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ⁷Department of Gastroenterology, Hopital Saint-Louis, APHP, Paris, France, ⁸PRINTO Coordinating Centre, Genoa, Italy, ⁹Inflammation, Chimiokines et Immunopathologie, INSERM UMR 996, Faculté de Pharmacie, Chatenay Mallabry, France, ¹⁰Université Paris Sud, Paris, France
Background/Purpose: Immunization against TNF Inhibitors (TNFi) is observed in 30-50% of patients with inflammatory rheumatic diseases. With most TNFi, anti-drug antibodies (ADA) lead to rapid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].